Semaglutide Should Transform Novo Nordisk's Prospects, CSO Says

 
• By Sten Stovall
  
Mads Krogsgaard Thomsen
Novo Nordisk CSO Sings Semaglutide's Praises • Source: Novo Nordisk A/S
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip